HCA Healthcare Q3 Earnings Beat Estimates on Higher Admissions

Zacks
Abrir em Zacks
HCA Healthcare Q3 Earnings Beat Estimates on Higher Admissions

HCA Healthcare, Inc. HCA reported third-quarter 2026 adjusted earnings per share (EPS) of $7.22, which beat the Zacks Consensus Estimate of $6.74. The bottom line advanced 3.7% year over year.

Revenues rose 3.6% year over year to $19.8 billion. The top line beat the Zacks Consensus Estimate of $19.4 billion.

The strong quarterly results benefited from higher same-facility admissions and solid emergency room visit growth. However, declining inpatient and outpatient surgeries, along with elevated operating expenses, partially offset these positives.

HCA Healthcare, Inc. Price, Consensus and EPS Surprise

HCA Healthcare, Inc. Price, Consensus and EPS Surprise

HCA Healthcare, Inc. price-consensus-eps-surprise-chart | HCA Healthcare, Inc. Quote

HCA’s Q3 Details

Same-facility equivalent admissions grew 3% year over year in the third quarter, beating our growth estimate of 2.2%. Meanwhile, same-facility admissions increased 2.7%, also surpassing our growth estimate of 2%.

Same-facility revenue per equivalent admission rose 0.6% year over year but came in lower than our growth estimate of 4.8%.

Same-facility inpatient surgeries fell 1.4% year over year, while same-facility outpatient surgeries dipped 3.7%. Same-facility emergency room visits increased 5.1% year over year in the quarter.

Salaries and benefits, supplies and other operating expenses increased 4.2% year over year to $16 billion. The metric came in higher than our estimate of $15.6 billion.

Adjusted EBITDA of $3.9 billion advanced 1.2% year over year, which beat our estimate of $3.8 billion.

HCA Healthcare operated 189 hospitals and roughly 2,600 ambulatory sites of care across 19 states and the United Kingdom as of Sept. 30, 2026.

HCA’s Q3 Financial Update

HCA Healthcare exited the third quarter with $908 million in cash and cash equivalents, down 12.7% from the 2025-end level. It had approximately $2.2 billion of available capacity under its credit facility at the end of the reported quarter.

Total assets of $63.5 billion increased 4.5% from the year-end 2025 figure.

Long-term debt, excluding debt issuance costs and discounts, was $42.8 billion, up 1.9% from the figure as of Dec. 31, 2025. Short-term borrowings and long-term debt due within a year totaled $8.1 billion.

Capital expenditures, excluding acquisitions, amounted to $1.4 billion during the quarter.

HCA’s Cash Flow

Cash flows from operating activities increased 1% year over year to $4.5 billion in the third quarter of 2026.

HCA Healthcare’s Capital Deployment Update

HCA bought back shares worth approximately $3 billion in the third quarter. It had about $4.2 billion remaining under its share repurchase authorization as of Sept. 30, 2026. The board also declared a quarterly cash dividend of 78 cents per share, payable on Dec. 29, 2026, to its shareholders of record as of Dec. 15.

HCA’s 2026 Guidance

The company maintained its revenue guidance of $77-$79.5 billion for 2026. Adjusted EBITDA remains projected between $15.4 billion and $16.1 billion.

Net income attributable to HCA Healthcare is still anticipated between $6.3 billion and $6.7 billion. EPS guidance remains at $28.70-$30.50.

HCA’s Zacks Rank & Key Picks

HCA currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space are Globus Medical, Inc. GMED, Collegium Pharmaceutical, Inc. COLL and TG Therapeutics, Inc. TGTX, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Globus Medical’s current-quarter earnings is pegged at $1.20 per share, suggesting 1.7% year-over-year growth. GMED beat earnings estimates in each of the trailing four quarters, with the average surprise being 27.9%. The consensus estimate for current-quarter revenues is pegged at $793 million, suggesting 3.1% year-over-year growth.

The Zacks Consensus Estimate for Collegium Pharmaceutical’s current-quarter earnings of $1.77 per share has remained stable over the past seven days. COLL beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 12.8%. The consensus estimate for current-quarter revenues is pegged at $215 million, suggesting 2.7% year-over-year growth.

The Zacks Consensus Estimate for TG Therapeutics’ current-quarter earnings of 37 cents per share has witnessed one upward revision in the past 30 days, against no movement in the opposite direction. The consensus estimate for TGTX’s current-quarter revenues is pegged at $247.2 million, suggesting 52.8% year-over-year growth.

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.

Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .

Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.

See Top Quantum Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
HCA Healthcare, Inc. (HCA): Free Stock Analysis Report
 
TG Therapeutics, Inc. (TGTX): Free Stock Analysis Report
 
Globus Medical, Inc. (GMED): Free Stock Analysis Report
 
Collegium Pharmaceutical, Inc. (COLL): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research